ak 2123 has been researched along with hydralazine in 2 studies
| Studies (ak 2123) | Trials (ak 2123) | Recent Studies (post-2010) (ak 2123) | Studies (hydralazine) | Trials (hydralazine) | Recent Studies (post-2010) (hydralazine) |
|---|---|---|---|---|---|
| 52 | 8 | 5 | 4,580 | 364 | 393 |
| Protein | Taxonomy | ak 2123 (IC50) | hydralazine (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 1.265 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.649 | |
| Lactoperoxidase | Bos taurus (cattle) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devi, PU; Rao, BS | 1 |
| Kagiya, TV; Kunugita, N; Mei, N; Norimura, T | 1 |
2 other study(ies) available for ak 2123 and hydralazine
| Article | Year |
|---|---|
Multimodality treatment using AK-2123, hydralazine, radiation & hyperthermia on a transplantable mouse tumour.
Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Sarcoma, Experimental; Triazoles; Vasodilator Agents | 1996 |
Modification of radio-thermo-chemotherapy by AK-2123 and hydralazine in tumor bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Radiation-Sensitizing Agents; Triazoles; Tumor Cells, Cultured | 1996 |